Growing community of inventors

Palo Alto, CA, United States of America

David R Swanson

Average Co-Inventor Count = 2.75

ph-index = 10

The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.

Forward Citations = 483

David R SwansonAtul D Ayer (4 patents)David R SwansonAnthony L Kuczynski (4 patents)David R SwansonDavid E Edgren (3 patents)David R SwansonBrian L Barclay (3 patents)David R SwansonJoseph C Deters (3 patents)David R SwansonJeri D Wright (2 patents)David R SwansonStephen C DeRosa (2 patents)David R SwansonFelix T Theeuwes (1 patent)David R SwansonPatrick S Wong (1 patent)David R SwansonDavid R Swanson (12 patents)Atul D AyerAtul D Ayer (97 patents)Anthony L KuczynskiAnthony L Kuczynski (37 patents)David E EdgrenDavid E Edgren (59 patents)Brian L BarclayBrian L Barclay (38 patents)Joseph C DetersJoseph C Deters (18 patents)Jeri D WrightJeri D Wright (20 patents)Stephen C DeRosaStephen C DeRosa (2 patents)Felix T TheeuwesFelix T Theeuwes (261 patents)Patrick S WongPatrick S Wong (162 patents)
..
Inventor’s number of patents
..
Strength of working relationships

Company Filing History:

1. Alza Corporation (12 from 1,062 patents)


12 patents:

1. 5326571 - Dosage forms comprising polymers comprising different molecular weights

2. 5208037 - Dosage forms comprising polymers comprising different molecular weights

3. 5186942 - Nicardipine therapy

4. 5096716 - Dosage form for administering calcium antagonist nicardipine

5. 5030456 - Dosage form for treating cardiovascular diseases

6. 4950486 - Dosage form for treating cardiovascular diseases

7. 4946687 - Dosage form for treating cardiovascular diseases

8. 4837111 - Dosage form for dispensing drug for human therapy

9. 4816263 - Dosage form for treating cardiovascular diseases comprising isradipine

10. 4484921 - Theophylline therapy utilizing osmotic delivery

11. 4439195 - Theophylline therapy

12. 4326525 - Osmotic device that improves delivery properties of agent in situ

Please report any incorrect information to support@idiyas.com
idiyas.com
as of
12/27/2025
Loading…